Baseline characteristics of the 33 trials included in the meta-analysis (n = 6882).

Abbreviations: PFS, progression-free survival; OS, overall survival; RCC, renal cell cancer; NSCLC, non-small-cell lung carcinoma; SCLC, small-cell lung cancer; CRC, Colorectal cancer; STS, soft tissue sarcoma; Bev, bevacizumab; GEM, gemcitabine; PTX, paclitaxel; NR, not reported; N/A, not applicable.

缩写说明：PFS（无进展生存期，progression-free survival）；OS（总生存期，overall survival）；RCC（肾细胞癌，renal cell cancer）；NSCLC（非小细胞肺癌，non-small-cell lung carcinoma）；SCLC（小细胞肺癌，small-cell lung cancer）；CRC（结直肠癌，Colorectal cancer）；STS（软组织肉瘤，soft tissue sarcoma）；Bev（贝伐珠单抗，bevacizumab）；GEM（吉西他滨，gemcitabine）；PTX（紫杉醇，paclitaxel）；NR（未报告，not reported）；N/A（不适用，not applicable）。